Evidence map›Paper›PMID 42788422›Full record

ArticleBiotechnology journal2026

Mammalian Expression and Mass Spectrometric Characterization of Highly Active Human Arylsulfatase A.

T Pal, M Dabarera, A Dutta, G Smolenski, B D Dickson, A Williamson, W Kelton

Abstract read
In one paragraph

Article in Biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

T Pal *Te Aka Mātuatua School of Science, University of Waikato, Hamilton, New Zealand.ORCID https://orcid.org/0009-0001-9311-217X
M Dabarera *Te Aka Mātuatua School of Science, University of Waikato, Hamilton, New Zealand.
A DuttaTe Aka Mātuatua School of Science, University of Waikato, Hamilton, New Zealand.
G SmolenskiMS3 Solutions, Ruakura Research Centre, Hamilton, New Zealand.ORCID https://orcid.org/0000-0003-0544-2687
B D DicksonTe Aka Mātuatua School of Science, University of Waikato, Hamilton, New Zealand.ORCID https://orcid.org/0000-0001-6860-903X
A WilliamsonTe Aka Mātuatua School of Science, University of Waikato, Hamilton, New Zealand.ORCID https://orcid.org/0000-0001-8139-1071
W KeltonTe Aka Mātuatua School of Science, University of Waikato, Hamilton, New Zealand.ORCID https://orcid.org/0000-0002-5513-6429

Funding

University of Waikato Seed Fund Grant
6 · The paper itself

Abstract

The lysosomal enzyme Arylsulfatase A (ARSA) plays a critical role in hydrolyzing sulfatides from within cells. While gene therapies for ARSA replacement have recently been approved, challenges remain in recombinantly producing large amounts of active ARSA, especially for research purposes where generating stable cell lines is cumbersome. A major bottleneck is the need to convert the active-site residue Cysteine at position 69 to formylglycine by a formylglycine-generating enzyme (FGE). Further, transporter mannose-6-phosphate receptors (M6PR) are required to mediate active transport of ARSA out of the cell. To address these issues, we have optimized a three-plasmid transient transfection approach that produces ARSA with active site conversion of over 70% as measured by mass spectrometry and is highly active in assays with a model substrate. We find the optimal ARSA:M6PR:FGE plasmid ratio to be 8:1:1, which balances active site conversion with total protein yield. This optimized protocol will assist in producing highly active ARSA for biochemical studies in research labs with access to standard cell culture facilities.

Indexed as

Cerebroside-SulfataseCatalytic DomainGlycineHEK293 CellsHumansMass SpectrometryPlasmidsReceptor, IGF Type 2Recombinant ProteinsTransfectionCerebroside-SulfataseGlycineN-formylglycineReceptor, IGF Type 2Recombinant ProteinsArylsulfatase Aformyl glycine modificationprotein expressionsulfatases

Identifiers

PMID42788422
PMCPMC13613566

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.